Short Interest in Gilead Sciences Rises By 3.1% (GILD)
Gilead Sciences (NASDAQ:GILD) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 98,473,543 shares, an increase of 3.1% from the July 15th total of 95,485,621 shares, AmericanBankingNews.com reports. Currently, 6.5% of the company’s stock are short sold. Based on an average daily volume of 14,643,274 shares, the days-to-cover ratio is presently 6.7 days.
In other Gilead Sciences news, Director Richard James Whitley sold 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $91.00, for a total transaction of $455,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of research firms have recently commented on GILD. Analysts at Argus initiated coverage on shares of Gilead Sciences in a research note on Monday. They set a “buy” rating and a $110.00 price target on the stock. Separately, analysts at Zacks upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating in a research note on Thursday. They now have a $111.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 6th. They now have a $97.00 price target on the stock. One research analyst has rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $103.32.
Shares of Gilead Sciences (NASDAQ:GILD) traded up 0.51% on Monday, hitting $92.92. The stock had a trading volume of 8,583,888 shares. Gilead Sciences has a 52-week low of $55.96 and a 52-week high of $94.34. The stock has a 50-day moving average of $87.92 and a 200-day moving average of $80.73. The company has a market cap of $140.5 billion and a price-to-earnings ratio of 20.94.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $7.89 EPS for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.